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BACKGROUND: Cell or tissue specific background may influence the consequences of expressing the 
Huntington's disease (HD) mutation. Aggregate formation is known to occur in skeletal muscle, but 
not heart of the R6/2 fragment HD model. 
OBJECTIVE: We asked whether aggregate formation and the expression and subcellular localization 
of huntingtin species was associated with mitochondrial dysfunction. 
METHODS: We analyzed levels of soluble HTT and HTT aggregates, as well as important fission and 
fusion proteins and mitochondrial respiratory chain activities, in quadriceps and heart of the R6/2 N-
terminal fragment mouse model (12 weeks, 160±10 CAG repeats). 
RESULTS: Soluble mutant HTT was present in both tissues with expression higher in 
cytoplasmic/mitochondrial than nuclear fractions. HTT aggregates were only detectable in R6/2 
quadriceps, in association with increased levels of the pro-fission factor DRP1 and its phosphorylated 
active form, and decreased levels of the pro-fusion factor MFN2. In addition, respiratory chain 
complex activities were decreased. In heart that was without detectable HTT aggregates, we found 
no evidence for mitochondrial dysfunction. 
CONCLUSION: Tissue specific factors may exist that protect the R6/2 heart from HTT aggregate 
formation and mitochondrial pathology. 




Huntington’s disease (HD) is a progressive movement disorder with dementia and 
behavioural abnormalities [1]. HD is caused by a CAG repeat expansion mutation in the 
huntingtin gene (HTT), encoding for the large huntingtin protein (HTT). Striatal and extra-
striatal, e.g. cortical, degeneration constitutes the neuropathological signature of HD. 
However, HTT is ubiquitously expressed and there is also evidence indicating that mutant 
HTT causes a peripheral phenotype, for instance in skeletal muscle [2, 3].  
The physiological function of wild-type HTT remains incompletely understood. HTT is 
predominantly found in the cytoplasm where it associates with the plasma membrane, 
mitochondria, lysosomes and the endoplasmatic reticulum [4-11]. Mutant HTT is 
predominantly localized in the cytoplasm but similar to wild-type HTT co-localizes also with 
the nucleus, endoplasmic reticulum, endosomes, Golgi-apparatus and mitochondria [12-15]. 
The mutation is thought to confer both a loss of physiological functions and a toxic gain of 
function, which is linked to the observation that mutant HTT species can form aggregates 
that may interfere with cellular functions [16].  
In tissues of HD models, including skeletal muscle and in cells from HD patients, 
mitochondrial dysfunction involving disturbed calcium homoeostasis, enhanced reactive 
oxygen species (ROS) production and reduced biogenesis has repeatedly been reported [17]. 
HTT was shown to associate with DRP1 on the outer mitochondrial membrane increasing its 
enzymatic activity leading to increased mitochondrial fragmentation [18-21]. In addition, 
mutant HTT may associate with TIM23 influencing the effectiveness of mitochondrial import, 
which is important for the mitochondrial unfolded protein response (UPRmt) [14]. Further to 
the direct influence of HTT on mitochondrial function, naturally occurring variability in genes 
relevant for fission and fusion significantly influenced motor age-at-onset independent of 
the CAG repeat expansion [22]. These findings indicate that mutant HTT influences 
mitochondrial biology. No single role of HTT in mitochondrial function has emerged; 
however, several lines of evidence in different model systems and human material point 
towards a role in fission and fusion regulation [18-21, 23, 24], a key element in mitochondrial 
quality control. In support of this notion, reducing DRP1 activity in HD models improved the 
HD phenotype suggesting mitochondrial quality control pathways may be treatment targets 
for HD disease modification [20].  
In the present study we investigated the relationship between the expression of full-length 
mutant HTT, the occurrence of HTT aggregates and mitochondrial biology in skeletal muscle 
and heart from the R6/2 fragment mouse model of HD. In contrast to brain, skeletal muscle 
is easy to access, including in humans. If a relationship existed between mutant HTT species 
and a biological phenotype in skeletal muscle, e.g. mitochondrial dysfunction, valuable 
insight into HD disease mechanisms could be gained with the potential to serve as peripheral 
biomarker. We hypothesised that 1) mutant HTT is expressed in skeletal muscle and heart; 
and 2) given the extant findings of increased mitochondrial fragmentation in HD models, and 
of mitochondrial abnormalities in skeletal muscle, that skeletal muscle and heart would 
show evidence of a shift of the fission and fusion balance towards mitochondrial fission, 
given that the N-terminal fragment model is a particularly aggressive model of HD.  
 
  
Materials and Methods 
Animals 
R6/2 transgenic mice (B6CBATg(HDexon1)62Gpb/1J) and their corresponding wild-type 
B6CBAF1/J were purchased from Jackson Laboratory. The R6/2 fragment model contains 
exon 1 with expanded CAG repeats of the human HTT gene [25]. For genotyping and for 
determination of the CAG repeat length (160 ± 10) DNA was extracted from tail biopsies 
[26]. Mice at 12 weeks were sacrificed by cervical dislocation, quadriceps and heart were 
dissected and immediately snap-frozen in liquid nitrogen and stored at -80°C. For 
immunohistochemistry tissues were snap-frozen in liquid nitrogen-cooled 2-methylbutane 
and stored at -80°C. For electron microscopy 12 weeks-old mice were perfused with 4% 
paraformaldehyde and tissues were immediately fixed in 2.5% glutaraldehyde. All work was 
performed according to local regulations and EU Directive 2010/63/EU.  
Animal care was in accordance with the United States Public Health Service Policy on 
Humane Care and Use of Laboratory Animals, and procedures were approved by the 
Institutional Animal and Use Committee of Psychogenics, Inc. (PHS OLAW animal welfare 




For western blotting the following antibodies were used: anti-DRP1 (dynamin-1-like protein, 
BD 611112) 1:1000 and anti-OPA1 (optic atrophy protein 1, BD 612606) 1:1000 from BD 
Biosciences. Anti-MFN1 (anti-mitofusin1, ab126575) 1:500, anti-MFN2 (mitofusin-2, 
ab50838) 1:1000; anti-NDUFA9 (NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 9, ab14713) 1:3000; anti-SDHA (succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, ab14715) 1:10000; anti-UQCRC2 (cytochrome b-c1 complex subunit 2, ab14745) 
1:6000; anti-MTCO1 (cytochrome c oxidase subunit 1, ab14705) 1:6000; anti-ATP5A 
(ab14748) 1:6000 and anti-citrate synthase (ab129095) 1:1000 from Abcam. For detection of 
the phosphorylation state anti-Phospho-DRP1 (Ser616) (3455, Cell Signaling) 1:1000 was 
used. For analysis of HTT aggregates the S829 (1:3000) antibody, kindly provided by Gillian 
Bates (UCL, UK), was used. As secondary antibodies goat anti-mouse IgG (H+L)-HRP (1:3000, 
1706516, Bio-Rad), goat anti-rabbit IgG (H+L)-HRP (1:10000, 111-035-003, Jackson 
ImmunoResearch) or rabbit anti-goat IgG (H+L)-HRP (1:10000, R21459, Life Technologies) 
were used.  
For immunohistochemistry the S829 antibody (1:400 in PBS, 5% horse serum, 0.05% Tween) 
and as secondary antibody donkey anti-sheep IgG (H+L) Alexa fluor 488 (1:400 in PBS, 
A11015, Thermo Fisher) were used. 
Total protein extraction, gel electrophoresis and western blot 
These methods were performed as described previously [28]. Tissues were lysed using a 
tissue lyser (Qiagen) in homogenization buffer (320 mM sucrose, 1 mM K+ EDTA, 10 mM 
Tris/HCl, pH 7.4, 1 µg/ml pepstatin, 1 µg/ml leupeptin and 1 mM PMSF) followed by 
repeated centrifugation at 600×g at 4°C. The supernatant was used for protein analysis. For 
western blot analysis protein samples were denatured in NuPAGE LDL sample buffer 
(NP0008, Thermo Fisher) and analyzed on 9% Bis-Tris gels in MOPS buffer (50 mM MOPS, 50 
mM Tris base, 0.2% SDS (w/v), 0.1 mM EDTA, pH 7.3) followed by western blotting on PVDF 
membranes in transfer buffer (25 mM bicine, 25 mM Bis-Tris, 1 mM EDTA, 20% methanol 
(v/v), pH 7.2). Analyses of HTT aggregates were performed on 6% Bis-Tris gels. Assembly of 
oxidative phosphorylation complexes was analyzed using blue native gel electrophoresis 
with 4%-16% gradient gels as described previously [29]. Protein extractions for analysis of 
the phosphorylation state were performed in RIPA buffer (10 mM Tris base, 0.1% SDS (w/v), 
1% Triton X-100 (v/v), 1% Na-deoxycholate (w/v), 5 mM EDTA, pH 7.4) containing 
phosphatase inhibitors (PhosSTOP, 04906837001, Sigma-Aldrich). For visualizing the total 
protein amount the membrane was incubated with Pierce Reversible Protein Stain Kit for 
PVDF membranes (Pierce, Rockford, USA) or Ponceau solution (2% Ponceau S (w/v), 3% 
trichloroacetic acid (w/v)) for nitrocellulose membranes (Bio-Rad). Data analysis was 
performed by densitometric quantification using the ImageQuant TL software (GE 
Healthcare). Protein levels were determined relative to total protein amount. 
Erenna Singulex SMC immunoassay for mutant HTT detection 
The MW1 antibody was developed by Dr. Paul Patterson [30]. 2B7 antibody generation and 
characterization were as previously described [31]. The 2B7 antibody was conjugated to 
magnetic particles (MPs), to a final concentration of 25 μg/mg of MPs, and the MW1 
antibody was labeled to a final concentration of 1 μg/μl, using the Erenna capture and 
detection reagent labeling kits from Merck-Millipore, following the manufacturer’s 
instructions. Conjugated/labeled antibodies were diluted in Assay Buffer (02-0474-00, 
Merck-Millipore) to 1:1200 and 1:4000, respectively, prior to performing the assay.  
The immunoassay was largely performed as previously described [32]. In brief, mouse tissue 
samples were pre-diluted in artificial CSF (aCSF) with 1% Tween-20 (v/v) and complete 
protease inhibitor (11 697 498 001, Roche) to a concentration of 10 µg/ml of total protein. 
Pre-diluted tissue samples and 2B7 antibody coupled to MPs were added to assay buffer 
containing 6% BSA (w/v), 0.8% Triton X-100 (v/v), 750 mM NaCl and complete protease 
inhibitor in a 96-conical assay plate (P-96-450V-C, Axygen). The plate was sealed and 
incubated on a shaker at room temperature for 1 h. Samples were washed on a magnetic 
rack, using a HydroFlex Microplate 8 Channel Washer (Tecan), in 1x Erenna Wash Buffer (02-
0111-03, Merck-Millipore). Afterwards MPs were incubated with MW1 detection antibody 
for 1 h at room temperature. Samples were again washed in 1x Erenna Wash Buffer on a 
magnetic rack in a HydroFlex washer. The antibody-antigen complex was transferred to a 
new 96-conical assay plate to eliminate nonspecific binding events to the plastic. After buffer 
aspiration the Elution Buffer B (02-0297-00, Merck-Millipore) was added to the plate for 5 
min of incubation while shaking. The eluted detection antibody was transferred to a Nunc 
384-well analysis plate (264573, Sigma-Aldrich) and neutralized with Buffer D (02-0368-00, 
Merck-Millipore). The analysis plate was spun down to eliminate foaming and bubble 
formation, sealed, and subsequently analyzed with the Erenna Immunoassay System (Merck-
Millipore). 
Subcellular fractionation 
For the Singulex assay tissues were lysed as described previously [33] but with buffer 
conditions suitable for the assay. All steps were performed on ice and at 4°C. 50 mg of tissue 
was minced using sharp scissors, suspended in 300 µl of STM buffer (250 mM sucrose, 50 
mM Tris-HCl pH 7.4, 5 mM MgCl2, 1 µg/ml pepstatin, 1 µg/ml leupeptin and 1 mM PMSF) 
and homogenized for 1 min at 1000 rpm using a Potter S homogenizer (Sartorius B. Braun). 
The homogenate was decanted into a 1.5-ml tube, remaining tissue fragments were re-
suspended in 300 µl of STM buffer and homogenization was repeated. The homogenates 
were combined, incubated for 30 min on ice and vortexed for 15 sec. After taking 40 µl of 
the total lysate (TL) for analysis the homogenate was centrifuged for 15 min at 800×g. The 
pellet was the nuclear fraction and the supernatant the cytoplasmic/mitochondrial fraction. 
The pellet was washed in 300-500 µl of STM buffer, vortexed for 15 sec and centrifuged for 
15 min at 500×g. The washing step was repeated and the pellet finally re-suspended in 200-
500 µl of NET buffer (20 mM Hepes pH 7.9, 1.5 mM MgCl2, 0.5 M NaCl, 0.2 mM EDTA, 1% 
Triton X-100 (v/v), 1 µg/ml pepstatin, 1 µg/ml leupeptin and 1 mM PMSF). The nuclear 
fraction was lysed by sonification, centrifuged at 9,000×g for 30 min and the resultant 
supernatant was the final nuclear fraction (NF). The cytoplasmic/mitochondrial fraction was 
centrifuged at 800×g for 10 min to remove cell debris and the supernatant was the final 
cytoplasmic/mitochondrial fraction (CM). For subcellular fractionation into cytoplasmic and 
mitochondrial fractions, the cytoplasmic/mitochondrial fraction was further purified as 
described [33]. 
Electron microscopy 
Two ultra-thin sections from different areas were used for electron microscopy. For 
quadriceps tissue the sections were prepared in longitudinal orientation to the fiber. Images 
of ultra-thin sections per sample were taken with a Jeol 1400 Transmission Electron 
Microscope (JEOL GmBH). For quantification five images per sample at ×12,000 
magnification were used. Images were exported to a tablet-PC (iPad2, Apple) and the 
mitochondrial area and number were evaluated using the Glow Draw application (The 
Othernet, LLC © Daniel Cota), followed by quantification using ImageJ software (ImageJ 
1.46r, Wayne Rasband, National Institutes of Health, USA). The median of individual results 
from each of the five images was calculated for the mitochondrial area and number [34]. 
Data acquisition and all analyses were done blinded to the genotype.  
Immunohistochemistry 
Quadriceps sections were cut in transverse orientation to the fiber direction at 10 µm. 
Sections were fixed for 10 min in acetone, washed with PBS followed by drying for 1 h at 
room temperature. The following procedures were performed in a humidified chamber: 
sections were blocked in blocking solution (5% goat serum (v/v) in PBS) for 45 min followed 
by incubation overnight at 4°C with the primary antibody. Sections were washed with PBS-T 
(0.05% Tween (v/v) in PBS) and incubated with the secondary antibody for 1 h in the dark at 
room temperature. Sections were embedded in Citifluor AF1 (R1320, Agar Scientific) 
containing DAPI (5 µg/ml, DAPI dilactate, D3571, Life Technologies). 
mRNA isolation and quantitative real-time PCR 
mRNA was isolated with the RNeasyPlus Mini Kit (74134, Qiagen) and 2 µg of RNA was 
reverse-transcribed into cDNA with the iScript cDNA synthesis kit (Bio-Rad). Quantitative 
real-time PCR (qPCR) was performed using SYBR® green supermix with the CFX384 Touch 
Real-Time PCR Detection Systems (Bio-Rad) as previously described [28, 34]. Primer 
sequences are listed in supplementary tables S3. For gene expression analysis in muscle 
samples Poldip3 (polymerase (DNA-directed), delta interacting protein 3) and Metap1 
(methionylaminopeptidase 1) were used as reference genes (R6/2 muscle: mean CV 0.17 and 
mean M Value 0.49), and Sdha (Succinate dehydrogenase [ubiquinone] flavoprotein subunit) 
and Metap1 for heart samples (mean CV 0.16 and mean M Value 0.46). The reference genes 
were selected according to Hellemans and colleagues [35] with homogenous stable cDNA 
level mean CV < 0.25 and mean M value < 0.5. Data were analyzed with the Bio-Rad CFX 
manager software (Bio-Rad).  
Mitochondrial DNA copy number 
The DNA was isolated with Puregene Core Kit A (Qiagen) as instructed by the manufacturer. 
The mitochondrial DNA (mtDNA) copy number was determined with quantitative real-time 
PCR with the CFX384 Touch Real-Time PCR Detection Systems (Bio-Rad) as previously 
described [28]. For detection of the mtDNA the D-loop region was used. As reference B2M 
(beta-2-microglobulin) encoded on the nuclear DNA was used [36-38]. Primer sequences are 
listed in supplementary table S4.  
Enzyme activity assays 
Tissue lysates were prepared as described previously [28]. Briefly, extractions were 
performed in homogenization buffer (320 mM sucrose, 1 mM K+ EDTA, 10 mM Tris/HCl, pH 
7.4, 1 µg/ml pepstatin, 1 µg/ml leupeptin and 1 mM PMSF) using a tissue lyser (Qiagen) at 
4°C. After centrifugation (600×g, 10 min at 4°C) the supernatant was used. 
Measurements of the activity of the respiratory chain enzyme complexes and of citrate 
synthase were performed as described previously [28, 39-42].  
ATP assay 
The amount of ATP was determined by using the ATP assay kit from Abcam (ab83555, 
abcam) as instructed by the manufacturer. The amount of ATP was calculated with the help 
of an ATP standard curve.  
Statistical analysis 
All data were evaluated blinded to the samples’ genotype. Statistical analysis was performed 
using GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego California 
USA). Data were examined for normal distribution using the Kolmogorov-Smirnov test. 
Parametric analysis of two groups was done with an unpaired t-test or with a Welch’s 
unequal variances t-test. For non-parametric analysis of two groups the Mann-Whitney test 
was used. For analysis of three or more groups one-way ANOVA was performed. 
  
Results 
Soluble mutant HTT is present in heart and quadriceps, while aggregates are only detectable 
in quadriceps  
We first examined whether soluble mutant HTT was expressed. Using the antibody 
combination 2B7/MW1 with the Singulex assay [31, 32, 43] there was clear evidence of 
soluble mutant HTT expression in total lysates of R6/2 transgenic (tg) quadriceps (Fig. 1A), 
and R6/2 heart muscle (Fig. 1D). We then investigated the distribution of total soluble 
mutant HTT in different cellular compartments. To this end we analyzed an enriched nuclear 
(NF) and cytoplasmic/mitochondrial fraction (CM) from quadriceps of R6/2 tg mice (Fig. 1B), 
and R6/2 tg heart (Fig. 1E). The cytoplasmic/mitochondrial fractions contained no detectable 
histone H3, a nuclear protein. The nuclear fractions were clearly enriched and contained no 
detectable GAPDH, a cytosolic protein, while some mitochondrial content remained since 
NDUFA9, a mitochondrial protein, was detectable at low levels. In R6/2 tg quadriceps (Fig. 
1C) the cytoplasmic/mitochondrial fraction clearly contained more soluble mutant HTT than 
the nuclear fraction (R6/2 P < 0.0001). In R6/2 tg heart mutant HTT was only in the 
cytoplasmic/mitochondrial fraction detectable with western blot using the 1C2 antibody that 
binds to polyQ repeats [25, 44] (Fig. 1F).  
The formation of HTT aggregates is a hallmark event in the pathogenesis of HD. We next 
examined whether HTT aggregates were detectable in quadriceps and heart muscle of R6/2 
tg mice. To this end we used two different methods, immunohistochemistry and western 
blot. We used the S829 antibody, which was raised against the N-terminal exon 1 HTT 
protein and was shown to detect aggregates in R6/2 tg mice [45, 46]. In quadriceps of R6/2 
tg mice aggregates were detectable on western blot (Fig. 2A) and also by confocal 
microscopy on tissue sections (Fig. 2B, G, Fig. S2). We then investigated the fractions 
enriched for nuclear or cytoplasmic/mitochondrial content. This revealed that aggregates 
were present in quadriceps of R6/2 tg mice with levels much higher in the nuclear fraction 
than in the cytoplasmic/mitochondrial fraction (Fig. 2C). 3D analysis of a section using 
confocal microscopy with z-stacking also demonstrated aggregates predominantly near the 
nucleus but very often aggregates appeared in close vicinity to nuclei rather than within 
them (Fig. 2G). 
In heart of R6/2 tg mice (Fig. 2D, E, Fig. S2), HTT aggregates were not evident using western 
blot or confocal microscopy. Furthermore aggregates were not detectable in the enriched 
nuclear or the cytoplasmic/mitochondrial fractions in heart of R6/2 tg mice (Fig. 2F). 
  
Fission and fusion protein imbalance is only observed in quadriceps of R6/2 tg mice 
Mitochondria form a dynamic network that undergoes fission and fusion to remain 
functional in the context of environmental and metabolic stress. Fission and fusion are 
mainly controlled by pro-fission and pro-fusion proteins. We investigated protein levels of 
the pro-fission dynamin-related protein (DRP1) and the pro-fusion proteins mitofusin 1 
(MFN1), mitofusin 2 (MFN2) and optic atrophy 1 (OPA1) [47, 48] in quadriceps and heart of 
R6/2 mice. DRP1 protein levels were significantly increased in R6/2 tg quadriceps (P < 0.01; 
Fig. 3A, B), whereas MFN2 protein levels were decreased compared to wild-type (wt) mice (P 
< 0.01). OPA1 and MFN1 protein levels were similar in tg and wt mice. In contrast to 
quadriceps, in R6/2 heart fission and fusion protein levels were similar in tg and wt mice (Fig. 
3C, D).  
At the mRNA level, compared to wt, levels of Dmn1l and Mfn1 were significantly increased in 
R6/2 tg quadriceps (Dmn1l P < 0.01; Mfn1 P < 0.01), while Opa1 mRNA level were decreased 
(P < 0.0001; Table 2). In R6/2 tg heart Opa1 transcripts were decreased (P < 0.05). The poor 
correlation of mRNA levels to protein levels can possibly be explained by post-transcriptional 
mechanisms involved in conversion of mRNA to protein, which are not well defined. In 
addition proteins may differ substantially in their in vivo half-life [49].  
 
Table 2. Expression of mitochondrial pro-fission and pro-fusion genes 
Relative mRNA level  Dmn1l Opa1 Mfn1 Mfn2 
R6/2 quadriceps 
mean ± SEM  
n ≥ 19 
wt 1.3 ± 0.07 1.4 ± 0.15 0.6 ± 0.07 0.7 ± 0.06 

















R6/2 heart  
mean ± SEM 
n ≥ 12 
wt 0.7 ± 0.09 0.9 ± 0.04 0.8 ± 0.05 0.8 ± 0.05 

















a) Welch's unequal variances t-test, b) Unpaired t-test 
 
Active phosphorylated DRP1 is increased only in quadriceps of R6/2 tg mice 
Absolute DRP1 protein levels do not necessarily reflect its enzymatic activity. The activity of 
DRP1 is regulated by a variety of post-translational modifications, including phosphorylation, 
S-nitrosylation, SUMO (small ubiquitin-like modifier)ylation, ubiquitination, and O-
GlcNAcylation, in response to diverse cellular stimuli [50, 51]. Phosphorylation at the amino 
acid residue Ser616 (position in human DRP1) leads to DRP1 activation and mitochondrial 
fragmentation [52, 53]. Once activated, DRP1 is recruited from the cytosol to mitochondria 
to induce mitochondrial fragmentation [51, 54, 55]. We next examined the amount of active 
DRP1 by using an antibody, which detects active phosphorylated DRP1 (p-DRP1). To confirm 
the specificity of the antibody we first treated HEK293 cells with the protonophor CCCP 
(carbonyl cyanide m-chlorophenyl hydrazone) to induce fission [56]. We detected an 
increase of p-DRP1, whereas absolute DRP1 level remained similar (Fig. S1), indicating that 
an increase in p-DRP1 signal reflects the increase of DRP1 enzymatic activity induced by 
CCCP. 
In lysates of R6/2 tg quadriceps we observed increased p-DRP1 levels (P < 0.01) and an 
increased p-DRP1/DRP1 ratio compared to wt mice (P < 0.05) indicating that active DRP1 
levels were elevated (Fig. 4A, B). We then performed subcellular fractionations for 
evaluating the distribution of DRP1 between the cytosolic and the mitochondrial 
compartment. DRP1 levels were higher in the quadriceps mitochondrial fractions of tg R6/2 
mice (69 ± 7%) than those of wt (31 ± 10%; Fig. 4C, D). In heart of R6/2 tg mice levels of p-
DRP1 were non-significantly lower (P = 0.07) in whole tissue lysates compared with wt; 
however, the p-DRP1/DRP1 ratio was similar in tg and wt hearts (Fig. 4E, F). In the 
mitochondrial fraction amounts of DRP1 were low with 8% in wt and 5% in tg hearts (Fig. 4G, 
H). In summary, higher levels of active DRP1 than in controls were only evident in tg 




Changes in the balance of mitochondrial pro-fission (p-DRP1/total DRP1) and pro-fusion 
factors (MFN1, MFN2, OPA1) can lead to abnormal mitochondrial network shape. We used 
electron microscopy to examine ultra-structural mitochondrial morphology and to analyze 
the size and number of mitochondria. We did not observe differences in cristae morphology 
in tg quadriceps or heart compared to wt (Fig. 5A, D). After quantification, we observed a 
non-significant increase in the amount of mitochondria in tg quadriceps of R6/2 mice (P = 
0.07), whereas the size was similar to wt tissue (Fig. 5A-C). Mitochondrial size and number in 
R6/2 heart tg mice (Fig. 5D-F) were similar to controls (Fig. 5J-L).  
In order to assess mitochondrial mass we analyzed citrate synthase activity, mitochondrial 
(mt) DNA copy number and Tfam (mitochondrial transcription factor A) mRNA expression or 
protein level. TFAM is an important regulator for mtDNA transcription and mtDNA copy 
number [57, 58]. Compared to wt tissue, citrate synthase activity, mtDNA copy number or 
Tfam mRNA levels were similar in R6/2 tg quadriceps and heart.  
Table 3. Analysis of mitochondrial mass 
Mitochondrial 
mass 
 Citrate synthase 












mean ± SEM  
n ≥ 6 
wt 0.06 ± 0.01 0.7 ± 0.04c 0.8 ± 0.14 1.1 ± 0.43 
tg 0.09 ± 0.02 0.8 ± 0.05c 1.1 ± 0.20 0.87 ± 0.16 








R6/2 heart  
mean ± SEM 
n ≥ 6 
wt 0.4 ± 0.05 0.7 ± 0.15 1.2 ± 0.17 0.8 ± 0.2 
tg 0.4 ± 0.02 0.9 ± 0.15 1.3 ± 0.11 1.2 ± 0.23 












The activity of complex I and complex IV is decreased in quadriceps of R6/2 tg mice 
An imbalance in mitochondrial fission and fusion can affect oxidative phosphorylation 
capacity and reduce ATP levels [59]. Therefore we next examined the activity of the 
respiratory chain complexes I, II/III and IV with spectrophotometry. To control for variations 
of mitochondrial mass we normalized our data to citrate synthase activity. In addition, we 
examined ATP levels in all tissues. In R6/2 tg quadriceps we observed decreased complex I 
and complex IV activities (P < 0.05), whereas the activity of complex II/III was similar to wt 
(Fig. 6A). However, ATP levels were similar in tg and wt quadriceps (Fig. 6B). In tg heart 
tissue the respiratory chain activity and ATP levels were similar to wt (Fig. 6C, D).  
In addition to the analysis of respiratory chain complex activities we assessed the assembly 
of the complexes using blue native gel electrophoresis. While the levels of most respiratory 
chain enzyme complexes were unaffected in R6/2 tg, levels of complex III assembly were 
increased in R6/2 tg quadriceps compared to wt (P < 0.05) (Table S1, S2). 
Discussion  
In this study we examined the subcellular localization of mutant HTT, and mitochondrial 
dynamics and function in skeletal and heart muscle of late-stage R6/2 mice. Soluble mutant 
HTT was present in both muscle tissues with soluble mutant HTT expression higher in 
cytoplasmic/mitochondrial than nuclear fractions. However, HTT aggregates were only 
detectable in R6/2 quadriceps, in association with increased levels of the pro-fission factor 
DRP1 and its phosphorylated active form, and decreased levels of the pro-fusion factor 
MFN2. In addition, respiratory chain complex activities were decreased. In heart, despite 
similarly high, or even higher, levels of soluble mutant HTT, there were no detectable HTT 
aggregates and no evidence for mitochondrial dysfunction. This suggests that R6/2 heart is 
protected from HTT aggregate formation and mitochondrial pathology. 
We first used the very sensitive Singulex assay, to assess whether tissues contained mutant 
HTT [31, 32, 43]. This is important because hypotheses of HD related downstream biological 
consequences are based on the assumption that mutant HTT is expressed in the analyzed 
tissues. We showed that soluble mutant HTT was indeed present in R6/2 heart and skeletal 
muscle samples. This is consistent with studies showing that soluble mutant HTT is 
expressed in a variety of non-CNS tissue of R6/2 tg mice e.g. skeletal muscle, liver and spleen 
[43].  
We next examined soluble mutant HTT subcellular expression. We detected soluble mutant 
HTT in cytoplasmic/mitochondrial and in nuclear fractions and consistent with data from 
brains of R6/2 and HdhQ150 mice, levels of HTT were highest in cytoplasmic/mitochondrial 
fractions [60, 61]. This indicates that full-length HTT, or fragments following cytoplasmic 
processing or CAG-repeat length-dependent aberrant splicing of HTT exon 1, can shuttle 
between the cytoplasm and the nucleus [12, 62-66]. It is unknown whether HTT contains a 
nuclear localization signal. However, HTT contains multiple HEAT (huntingtin, elongation 
factor 3, the PR65/A subunit of protein phosphatase 2A and the lipid kinase Tor) repeat 
sequences [67]. Proteins harboring HEAT domains often mediate protein-protein 
interactions and intracellular transport, including nucleocytoplasmic shuttling [68]. HTT 
contains a nuclear export signal (NES) in the C-terminal region, which is strictly conserved 
among species [62]. In addition HTT has within the first N-terminal 17 amino acids a 
translocated promoter region that acts as nuclear export signal [64]. Increasing polyQ 
expansions reduce its nuclear export and cause nuclear accumulation and aggregation of 
HTT [64]. The formation of intra-nuclear HTT aggregates is a pathological hallmark in human 
HD brains [70]. Therefore, we next examined whether our peripheral tissues contained 
aggregates. Consistent with previous findings we detected aggregates in total lysate of R6/2 
exon 1 fragment model skeletal muscle but not heart [45, 71-73]. Also in HdhQ150 mice 
aggregates have been detected in a wide range of peripheral tissues at 22 months of age, 
such as skeletal muscle, liver and kidney [74], while similar to our findings in heart of 
HdhQ150 mice aggregates could not be identified [74]. In vitro studies have shown that 
aggregation will not occur until the monomer concentration exceeds a certain critical 
concentration [75]. The aggregation process of the exon 1-derived fragment occurs in a time, 
concentration and polyQ repeat length dependent manner [75]. It is possible that N-terminal 
mutant exon 1-derived protein concentrations do not exceed that critical concentration in 
heart muscle samples. In contrast to in vitro aggregation kinetics [75] high amounts of 
soluble mutant HTT in vivo do not always correlate with the presence of aggregates. In R6/2 
tg testis high level of the soluble form have been detected but no aggregates were observed. 
In contrast, other tissues with similar expression levels of soluble mutant HTT, as for 
example liver, were characterized by aggregate formation [43]. This discrepancy suggests 
that many factors such as the ability of cells to divide, cell specific expression levels and 
subcellular distribution of mutant HTT may determine whether aggregation occurs [76]. 
Furthermore, age-dependent aggregate formation may differ between tissues. In R6/2 tg 
mice aggregates have been detected in e.g. striatum at 2 weeks of age, in cortex at 4 weeks 
and in in skeletal muscle at 8 weeks of age. [45]. This supports the notion that some tissues 
are more prone to aggregation than others.  
We found highest aggregate levels in the nuclear fraction of R6/2 skeletal muscle. However, 
HTT aggregates were often localized adjacent to the nuclei rather than within them, and 
cytoplasmic aggregates were also clearly present, similar to findings in cortex of zQ175 mice 
[69] and striatum of R6/2 mice [78]. Nuclear and cytoplasmic HTT aggregates can interfere 
with nucleocytoplasmic protein and mRNA transport, which has been shown in striatum and 
cortex of both R6/2 tg mice and zQ175, in human HD post-mortem brain tissue and in cell 
models expressing mutant HTT exon 1 [61, 69, 79]. Aggregate-mediated disruption of 
nucleocytoplasmic transport may thus be a critical event leading to pathology by affecting a 
number of cellular processes. We therefore next asked whether the presence of aggregates 
was associated with a biological phenotype. We investigated mitochondrial fission and 
fusion given the evidence indicating fission and fusion imbalance in animal models and in 
human post-mortem brain [18, 19, 21, 23, 24]. Similar to aggregate formation, abnormal 
fission and fusion was limited to R6/2 skeletal muscle in which levels of total and activated 
DRP1 were increased, concomitant with reduced MFN2 levels, and a respiratory chain 
enzyme complex I and IV deficiency. This is similar to what has been observed in HD 
lymphoblasts and Hdh(Q111) striatal cells [19] lending further support to the notion of a 
shift of the fission and fusion balance towards fission in HD. In contrast, in R6/2 tg heart, in 
which there was no detectable aggregate formation, there was no evidence of any 
mitochondrial phenotype. 
In summary, abnormal mitochondrial fission and fusion and respiratory chain defects were 
only evident in R6/2 tg skeletal muscle that had HTT aggregates. Fission and fusion maintain 
mitochondrial homeostasis and are essential for mitochondrial quality control [80]. 
Mitochondrial quality control is tightly associated with mitochondrial protein homeostasis 
which is maintained by mtUPR, a signaling pathway linking mitochondria with the nucleus 
[81]. Inhibition of the nucleocytoplasmic transport by mutant HTT aggregates may lead to 
severe defects in mitochondrial quality control pathways and impact the ability to respond 
to stress.  The striking differences in aggregate formation and mitochondrial function 
between skeletal muscle and heart in the R6/2 model indicate that differences in these 
tissues may have a substantial modifying effect on HD pathogenesis. The underlying 
mechanisms of disease modification may warrant further exploration. 
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